The global platelet aggregation devices market size reached US$ 525.0 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 744.7 Million by 2028, exhibiting a growth rate (CAGR) of 5.9% during 2023-2028.
Platelet aggregation devices comprise adenosine-diphosphate (ADP), thrombin, and ristocetin-induced platelet aggregation (RIPA). These devices are used to diagnose patients with inherited and acquired platelet function disorders, such as excessive bleeding, arterial thrombotic, stroke, and myocardial infarction. They assist in transfusing medicines, pre-surgery tests, and clinical settings to monitor the response of antiplatelet therapies and assess perioperative bleeding risk. At present, due to the launch of new potential biomarkers and technologies, platelet aggregation devices are finding extensive application in personalizing antiplatelet drugs and monitoring the efficacy of various types of pro-hemostatic therapies around the world.
Platelet Aggregation Devices Market Trends:
The rising instances of platelet aggregation among patients diagnosed with coronavirus disease (COVID-19) are strengthening the growth of the market. Moreover, due to the growing prevalence of colon cancer, cardiovascular diseases, Kawasaki condition, acute coronary syndrome (ACS), acute ischemic stroke, and acute rheumatic disorders across the globe, there is an increase in the risk of bleeding. This acts as another key factor impelling the growth of the platelet aggregation devices market for clinical management of platelet function disorders. In addition, a significant rise in the aging population suffering from chronic diseases is contributing to the market growth. Apart from this, leading manufacturers are launching novel products to expand their product portfolio and retain a competitive edge in the market. They are also focusing on developing new and simpler point-of-care (POC) diagnostic devices. These devices rely on the latest methodologies for helping in the rapid evaluation of inherited and acquired bleeding disorders and antiplatelet therapies. This, coupled with the increasing need for POC diagnostic devices to fulfill the healthcare demand of the large population, is projected to drive the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global platelet aggregation devices market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, type, application and end user.
Breakup by Product:
Consumables and Accessories
Breakup by Type:
Breakup by Application:
Breakup by End User:
Research and Academic Institutes
Breakup by Region:
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aggredyne Inc., Chrono-Log Corporation, F. Hoffmann-La Roche AG, Grifols S.A., Hart Biologicals Ltd., Helena Laboratories Corporation, LAbor BioMedical Technologies GmbH, Matis Medical Inc., Sentinel Ch. S.P.A., Siemens AG, Sienco Inc., Sysmex Corporation and WerfenLife SA.
Base Year of the Analysis
Product, Type, Application, End User, Region
Asia Pacific, Europe, North America, Latin America, Middle East and Africa
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Aggredyne Inc., Chrono-Log Corporation, F. Hoffmann-La Roche AG, Grifols S.A., Hart Biologicals Ltd., Helena Laboratories Corporation, LAbor BioMedical Technologies GmbH, Matis Medical Inc., Sentinel Ch. S.P.A., Siemens AG, Sienco Inc., Sysmex Corporation and WerfenLife SA
10% Free Customization
Report Price and Purchase Option
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The global platelet aggregation devices market was valued at US$ 525.0 Million in 2022.
We expect the global platelet aggregation devices market to exhibit a CAGR of 5.9% during 2023-2028.
The sudden outbreak of the COVID-19 pandemic has led to the increasing demand for platelet aggregation devices for treating platelet aggregation disorder, that is caused as a side-effect among the coronavirus-infection patients.
The rising prevalence of various chronic diseases, such as cardiovascular disorders, colon cancer, Kawasaki condition, etc., along with the growing adoption of platelet aggregation devices for clinical management of platelet function disorders, is primarily driving the global platelet aggregation devices market.
Based on the product, the global platelet aggregation devices market has been divided into systems, reagents, and consumables and accessories. Among these, reagents currently exhibit a clear dominance in the market.
Based on the type, the global platelet aggregation devices market can be categorized into four channel, dual channel, and eight channel. Currently, four channel accounts for the majority of the global market share.
Based on the application, the global platelet aggregation devices market has been segregated into clinical applications, research applications, cardiovascular applications, orthopedic applications, and others, where clinical applications currently hold the largest market share.
Based on the end user, the global platelet aggregation devices market can be bifurcated into hospitals, diagnostic laboratories, research and academic institutes, and others. Currently, hospitals exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global platelet aggregation devices market include Aggredyne Inc., Chrono-Log Corporation, F. Hoffmann-La Roche AG, Grifols S.A., Hart Biologicals Ltd., Helena Laboratories Corporation, LAbor BioMedical Technologies GmbH, Matis Medical Inc., Sentinel Ch. S.P.A., Siemens AG, Sienco Inc., Sysmex Corporation, and WerfenLife SA.
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.